Cleerly Secures CPT Category I Code for AI-QCT Advanced Plaque Analyses

After Five Years of Collaboration, Cleerly’s Innovative Technology Gains Permanent Recognition

Cleerly Secures CPT Category I Code for AI-QCT Advanced Plaque Analyses

Cleerly Media Contact

oneer in advanced cardiovascular imaging, is thrilled to announce that the American Medical Association (AMA) has approved a CPT Category I code for its AI-QCT advanced plaque analyses. This significant milestone, set to take effect January 1, 2026, marks a transformative step in the recognition and reimbursement of AI-driven technologies aimed at improving patient outcomes in cardiovascular care.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241028156660/en/

Cleerly Secures CPT Category I Code for AI-QCT Advanced Plaque Analyses (Photo: Business Wire)

The newly assigned CPT code signifies a transition from the Category III codes approved in 2020, which were intended as a temporary measure while additional data was gathered. Category I codes are reserved for established medical procedures and technologies, providing permanent recognition that facilitates broader adoption, coverage and reimbursement across healthcare systems.

Dr. James K. Min, Founder and CEO of Cleerly, expressed his excitement about this achievement, stating, “We are delighted that the American Medical Association has officially approved our request for a CPT Category I code for Cleerly’s AI-QCT advanced plaque analyses. Our team at Cleerly initiated this process with the AMA more than five years ago, and we could not be more thankful to the many societies and physicians that have supported us in the process. This approval shows the importance and power of AI and advanced imaging technologies in clinical practice.

“It’s been a very exciting time here at Cleerly—beyond the Category I CPT Code, we also saw five of seven Medicare Administrative Contractors finalize a coverage determination for Cleerly’s advanced plaque analysis. Both of these decisions will significantly expand the access of our personalized heart disease technology to Medicare beneficiaries and will encourage a paradigm shift in cardiovascular care.”

Cleerly remains committed to advancing cardiovascular evaluation through noninvasive advanced imaging to improve patient outcomes. For more information about Cleerly and its AI-QCT technology, please visit www.cleerlyhealth.com.

About Cleerly®

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: www.cleerlyhealth.com.